Advances in Proteomics for Personalized Medicine
Author Information
Author(s): Albrecht Vincent, Müller-Reif Johannes, Nordmann Thierry M., Mund Andreas, Schweizer Lisa, Geyer Philipp E., Niu Lili, Wang Juanjuan, Post Frederik, Oeller Marc, Metousis Andreas, Bach Nielsen Annelaura, Steger Medini, Wewer Albrechtsen Nicolai J., Mann Matthias
Primary Institution: Max Planck Institute of Biochemistry
Hypothesis
How can mass spectrometry-based proteomics and artificial intelligence be integrated to improve personalized medicine?
Conclusion
The integration of mass spectrometry-based proteomics and AI has the potential to revolutionize personalized medicine by enhancing diagnostics and treatment strategies.
Supporting Evidence
- Mass spectrometry–based proteomics is ready to transform clinical diagnostics.
- Spatial proteomics revolutionizes disease mechanism studies.
- Population-scale plasma proteomics studies define a new era of biomarker discovery.
- Clinical proteomics requires regulatory compliance and clear medical value.
- AI transforms proteomic data acquisition, analysis, and clinical decision support.
Takeaway
Scientists are using advanced technology to study proteins in our bodies, which can help doctors find diseases earlier and create better treatments.
Methodology
The symposium discussed technological advances in mass spectrometry-based proteomics and AI applications in clinical settings.
Potential Biases
Potential biases in sample collection and analysis methods could affect the reliability of findings.
Limitations
Challenges include regulatory compliance, standardization, and the need for robust business cases for clinical adoption.
Participant Demographics
Experts from various countries and fields, including technology developers and medical practitioners.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website